MCWS
BMRN icon

McKinley Carter Wealth Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

McKinley Carter Wealth Services’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100
Closed -$8K – 187
2018
Q1 		$8K Buy
+100
New +$8.58K ﹤0.01% 384

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

McKinley Carter Wealth Services's BMRN Position: Q2 2018 in Review

McKinley Carter Wealth Services sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 100 shares — an estimated $8K sold.

McKinley Carter Wealth Services first reported a position in BMRN in Q1 2018 and held it in 1 quarter. The position peaked at $8K in Q1 2018. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • McKinley Carter Wealth Services reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • McKinley Carter Wealth Services sold 100 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $8K.
  • McKinley Carter Wealth Services first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • McKinley Carter Wealth Services's BioMarin Pharmaceuticals position peaked at $8K in Q1 2018.
  • 449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on McKinley Carter Wealth Services's 13F filing for Q2 2018, filed 7 Dec 2018.